Samuel Strober awarded $6.6 million from state stem cell agency

Dr. Samuel Strober
Dr. Samuel Strober

SAMUEL STROBER, MD, a professor of medicine, was awarded $6.6 million by the governing board of the California Institute for Regenerative Medicine on Dec. 15 to conduct a phase-1 clinical trial to test a new way of inhibiting the rejection of transplanted kidneys.

The award marks the 10th clinical trial funded by the institute in 2016.

Dr. Strober specializes in the treatment of autoimmune diseases such as systemic lups erythematosus and rheumatoid arthritis. He has practiced rheumatology at Stanford for more than 30 years. He has a special interest in lupus kidney disease.

The clinical trial underwritten by the California stem cell agency award will test whether injecting blood stem cells and T cells from the kidney donor at the time of transplant will enable the recipient to more readily accept the new organ.

Read more about the trial and the award, which the institute called “deceptively simple,” in a blog post about the awards.